From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme
Abstract
Targeting specific protein–protein interactions, particularly those involving DNA methyltransferases (DNMTs), offers a promising strategy to resensitise glioblastoma multiforme cells to temozolomide. Glioblastoma multiforme is a highly aggressive brain cancer with a poor prognosis. The long-term efficacy of standard treatment, including temozolomide, is limited due to resistance development. Temozolomide resistance, often due to MGMT overexpression owing to global DNA hypomethylation and complex epigenetic regulation, significantly limits its efficacy. Thus, we developed site-specific DNMT1 inhibitors using peptide-based protein complex disruptors. Their design was guided by AlphaFold2 multimer, which provided insights into the interaction domains between DNMT1 and its protein partners. Peptides mimicking these interaction domains were synthesised and evaluated in a glioblastoma multiforme model. Our studies identified a peptide, namely PPDM2203, that specifically disrupts the DNMT1/DMAP1 interaction. This peptide did not induce global DNA hypomethylation but selectively inhibited DNMT1 activity at specific sites. Moreover, this peptide exhibited significant antitumoral properties, including sensibilisation to temozolomide, site-specific DNA methylation inhibition, cell proliferation, invasion and cytotoxicity. Therefore, the use of AlphaFold2 led to a peptide and offers a novel approach to selectively inhibit DNMT1 activity, enhancing the efficacy and specificity of existing DNMT1 inhibitors. This strategy underscores the potential for developing advanced therapeutic agents that minimize the risk of global DNA hypomethylation and its associated oncogenic effects.
Related
- Progesterone Receptor Expression in Different Regions of Glioblastoma Multiforme and in an In Vitro Model
- LINFOMA VITREORRETINIANO PRIMÁRIO APÓS TRATAMENTO DE GLIOBLASTOMA MULTIFORME: DESAFIOS DIAGNÓSTICOS E TERAPÊUTICOS
- miR-770 as a potential regulator of DNA methylation-related gene expression in glioblastoma: from in silico prediction to functional validation
- Combined HDAC and ATM inhibition with radiation in preclinical glioblastoma models
- Pannexin 1 inhibition reduces tumorigenic properties of patient-derived glioblastoma cells through the HIPPO and Wnt signalling pathways
BibTeX
@article{besson2026from,
title = {{From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme}},
author = {Jean-Maxime Besson and Alain Chavanieu and Arulraj Nadaradjane and Pierre-François Cartron and Marie Lopez},
journal = {RSC Medicinal Chemistry},
year = {2026},
month = jun,
doi = {10.1039/d5md00988j},
url = {https://hal.science/hal-05843661v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme
AU - Jean-Maxime Besson
AU - Alain Chavanieu
AU - Arulraj Nadaradjane
AU - Pierre-François Cartron
AU - Marie Lopez
PY - 2026
DA - 2026/06/11
JO - RSC Medicinal Chemistry
DO - 10.1039/d5md00988j
UR - https://hal.science/hal-05843661v1
AB - Targeting specific protein–protein interactions, particularly those involving DNA methyltransferases (DNMTs), offers a promising strategy to resensitise glioblastoma multiforme cells to temozolomide. Glioblastoma multiforme is a highly aggressive brain cancer with a poor prognosis. The long-term efficacy of standard treatment, including temozolomide, is limited due to resistance development. Temozolomide resistance, often due to MGMT overexpression owing to global DNA hypomethylation and complex epigenetic regulation, significantly limits its efficacy. Thus, we developed site-specific DNMT1 inhibitors using peptide-based protein complex disruptors. Their design was guided by AlphaFold2 multimer, which provided insights into the interaction domains between DNMT1 and its protein partners. Peptides mimicking these interaction domains were synthesised and evaluated in a glioblastoma multiforme model. Our studies identified a peptide, namely PPDM2203, that specifically disrupts the DNMT1/DMAP1 interaction. This peptide did not induce global DNA hypomethylation but selectively inhibited DNMT1 activity at specific sites. Moreover, this peptide exhibited significant antitumoral properties, including sensibilisation to temozolomide, site-specific DNA methylation inhibition, cell proliferation, invasion and cytotoxicity. Therefore, the use of AlphaFold2 led to a peptide and offers a novel approach to selectively inhibit DNMT1 activity, enhancing the efficacy and specificity of existing DNMT1 inhibitors. This strategy underscores the potential for developing advanced therapeutic agents that minimize the risk of global DNA hypomethylation and its associated oncogenic effects.
SN - 2632-8682
ER -